Advancing Neuropsychiatric Drug Discovery | Adgyl Lifesciences
Scientific Webinar Series · Series 1

Advancing neuropsychiatric drug discovery

Preclinical models for Major Depressive Disorder (MDD) & Post-Traumatic Stress Disorder (PTSD)

◷
Date 4 November 2026
◆
Time 9:30 AM – 10:30 AM EST
◉
Format Online webinar
Register for the webinar →

Building better models for neuropsychiatric drug discovery

Developing effective therapies for MDD and PTSD remains challenging due to the complexity of modelling human behaviour, treatment resistance and the preclinical-to-clinical translational gap.

This webinar will explore validated preclinical models for MDD and PTSD, model selection strategies, relevant behavioural paradigms, and integrated behavioural and biomarker assessments.

Learn how translational endpoints can enhance clinical relevance, strengthen candidate selection and help de-risk neuropsychiatric drug discovery programmes.

The challenges behind translation

Neuropsychiatric drug discovery requires models that can capture complex disease biology and provide meaningful translational insights.

01

Modelling human behaviour

Capturing complex behavioural phenotypes in preclinical models remains a significant scientific challenge.

02

Treatment resistance

Understanding treatment response and resistance is essential for improving candidate selection.

03

Translational gap

Connecting preclinical findings with clinically meaningful outcomes remains a critical hurdle.

04

Clinical endpoints

Selecting relevant behavioural and biomarker endpoints can strengthen clinical relevance.

From model selection to translational confidence

A carefully designed preclinical strategy can improve the relevance of study outcomes and support better decision-making throughout drug discovery.

  • ✓ Selection of relevant and validated preclinical models
  • ✓ Capturing appropriate behavioural paradigms
  • ✓ Integrated behavioural and biomarker assessments
  • ✓ Identification of relevant translational endpoints
  • ✓ Practical discussion through 1–2 case studies

What will be explored

The session will examine how preclinical model selection, behavioural assessments and biomarkers can be integrated to generate more clinically relevant insights.

Practical case study discussions will highlight how these approaches can support candidate selection and reduce translational risk.

Practical scientific insights · Case study discussion

What attendees will take away

01

Validated models

Explore validated preclinical models for Major Depressive Disorder and PTSD and their application in drug discovery.

02

Translational endpoints

Understand how behavioural and translational endpoints can improve clinical relevance.

03

Better candidate selection

Learn how integrated assessments can strengthen candidate selection and help de-risk discovery programmes.

Sachin Joshi

Meet the speaker.

Sachin Joshi, M.Pharm, MBA, PGDAW
Preclinical Pharmacology & Translational Research

With 22+ years of experience in drug discovery and CRO services, Sachin specializes in preclinical pharmacology and translational research. His scientific contributions include international publications, 15+ conference abstracts, and programs that have advanced three discovery-stage molecules into clinical trials.

Reserve your place for the session

Join us to explore practical approaches to preclinical modelling and translational assessment in neuropsychiatric drug discovery.

4 November 2026 · 9:30 AM – 10:30 AM EST
Register for the webinar →

Advancing neurodegenerative drug discovery

Preclinical models for Parkinson’s Disease, Alzheimer’s Disease & ALS.

Key challenges Lack of predictive models, biomarker validation, patient heterogeneity and complex disease mechanisms.
Scientific approach Selection of relevant models, translatable endpoints, better candidate selection and case study discussion.
Key takeaway Practical insights into disease models for Parkinson’s disease, Alzheimer’s disease and ALS.